Krystal Biotech KRYS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Krystal Biotech (KRYS) Business Model and Operations Summary
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Key Insights
Krystal Biotech (KRYS) Core Market Data and Business Metrics
Latest Closing Price
$174.58Market Cap
$5.05 BillionPrice-Earnings Ratio
98.08Total Outstanding Shares
28.81 Million SharesTotal Employees
275Dividend
No dividendIPO Date
September 20, 2017SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
2100 Wharton Street, Pittsburgh, PA, 15203
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $-89.82 Million |
| Net Cash Flow From Financing Activities, Continuing | $27.20 Million |
| Net Cash Flow From Investing Activities, Continuing | $-89.82 Million |
| Exchange Gains/Losses | $-4,000 |
| Net Cash Flow From Operating Activities, Continuing | $63.34 Million |
| Net Cash Flow From Financing Activities | $27.20 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations After Tax | $52.37 Million |
| Diluted Earnings Per Share | $1.78 |
| Net Income/Loss Attributable To Parent | $52.37 Million |
| Costs And Expenses | $184.12 Million |
| Net Income/Loss | $52.37 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $52.37 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $54.27 Million |
| Other Comprehensive Income/Loss | $54.27 Million |
| Comprehensive Income/Loss | $54.27 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $6.95 Million |
| Fixed Assets | $156.59 Million |
| Liabilities | $96.47 Million |
| Accounts Payable | $5.58 Million |
| Equity Attributable To Parent | $885.85 Million |
| Other Current Liabilities | $83.95 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||